Antidepressants
- PDF / 169,749 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 100 Downloads / 175 Views
1
S
Intracranial meningioma recurrence: 11 case reports In a retrospective study of 105 patients, who presented from 2011 to 2014 after primary meningioma resection, 11 patients (3 men and 8 women) aged 36–66 years were described, who developed intracranial meningioma recurrence during treatment with bupropion, citalopram, escitalopram, fluoxetine, paroxetine or sertraline for depression [routes, frequencies and outcomes not stated]. The patients, who had grade I–III intracranial meningioma, had undergone resection of meningioma. The patients had been receiving antidepressants post-resection (7 patients), pre-resection (1 patient) and pre- and post-resection (3 patients), comprising of sertraline 25–100mg (4 patients), escitalopram 5–20mg (2 patients), citalopram 20mg (2 patients), paroxetine 40mg (one patient), fluoxetine 20mg (one patient) and bupropion 150mg (one patient). The patients developed intracranial meningioma recurrence following 1.9–10.4 years of anti-depressants initiation. Author comment: "Even though [selective serotonin reuptake inhibitor] use has been shown to be neuroprotective against gliomas, in contrast, our study shows that [antidepressants] use was associated with increased recurrence rates." Kohli KM, et al. Antidepressant use in patients with meningioma: is there an association with tumor recurrence?. Neurosurgical Focus 44: E14, No. 6, Jun 2018. Available from: URL: http://doi.org/10.3171/2018.3.FOCUS17797 803434204 USA
0114-9954/19/1779-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 16 Nov 2019 No. 1779
Data Loading...
